MDT Q3 FY2026 Earnings: MiniMed Separation Costs Mask Strongest Growth in 10 Quarters
Medtronic delivered Q3 FY2026 revenue of $9.02 billion — its highest growth rate in 10 quarters at 8.7% year-over-year — with non-GAAP EPS of $1.36 beating consensus by $0.02. The stock fell 3.2% anyway. The 10-Q filing reveals why: $306-356M in MiniMed separation costs are front-loaded into the income statement, a $1.146B antitrust verdict went unmentioned in the press release, and Medical Surgical's $19.8B goodwill sits on a cushion of just 12%. Cardiovascular acceleration — up 13.8% with PFA capturing 80% of the EP market — is the real story, but the separation repricing makes it harder to see.